Join waitlist

Tirzepatide injection sites

Mounjaro and Zepbound use the same three areas: abdomen, thigh, and the back of the upper arm. Lilly’s instructions say to use a different site each week.

Free 3-day trial · no credit card · iOS & Android
✓ You're on the list. One email at launch.
THE APPROVED SITES

Abdomen · thigh · upper arm — and Lilly explicitly recommends a different site each week, even if you stay in the same area.

Per Mounjaro and Zepbound instructions for use, Eli Lilly. Not medical advice — ask your prescriber to demonstrate technique.

SEC. 02

What the app does

F—01

Rotate the site

The app remembers where you injected last and suggests where to go next. No more guessing.

F—02

Log the shot

Dose, site, side effects — four seconds, done. Editable forever, exportable for your doctor.

F—03

Shot history

Every injection on a timeline with dose, site and notes — synced to a real account across devices.

F—04

Get reminded

Morning-of, hour-before, and a follow-up if you forget. Weekly doses stop slipping through.

F—05

Set your day

Pick your shot day once. The app builds the week around it — countdown, calendar, history.

F—06

Windows encoded

Missed-dose and change-day rules for your exact medication, built into the schedule logic.

SEC. 03

Q & A

Can someone else inject my arm?Q—01 +
The back of the upper arm is hard to reach yourself — the official instructions suggest a caregiver for that site.
Same rules as semaglutide?Q—02 +
The approved areas are the same; the rotation advice is if anything more explicit for tirzepatide. The dosing windows differ though — 4-day catch-up, 3-day change gap.
How does the app help?Q—03 +
Every shot logs its site; the rotation view shows the last six weeks and highlights where to go next.
When does it launch?Q—04 +
In development now. Waitlist members get first access — US, Canada, UK, Australia and New Zealand, on the App Store and Google Play.

Your next shot,
on time.

One email at launch · free trial · no credit card

No spam — just one launch announcement
✓ You're on the list. Talk soon.